Louise Vedtofte

936 total citations
19 papers, 746 citations indexed

About

Louise Vedtofte is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Physiology. According to data from OpenAlex, Louise Vedtofte has authored 19 papers receiving a total of 746 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 5 papers in Physiology. Recurrent topics in Louise Vedtofte's work include Diabetes Treatment and Management (13 papers), Diabetes Management and Research (6 papers) and Diet and metabolism studies (5 papers). Louise Vedtofte is often cited by papers focused on Diabetes Treatment and Management (13 papers), Diabetes Management and Research (6 papers) and Diet and metabolism studies (5 papers). Louise Vedtofte collaborates with scholars based in Denmark, United States and Germany. Louise Vedtofte's co-authors include Tina Vilsbøll, Jens J. Holst, Filip K. Knop, Mikkel Christensen, Julie Rask Larsen, Anders Fink‐Jensen, Hans Søe Riis Jespersen, Claus Thorn Ekstrøm, Christoph U. Correll and Jimmi Nielsen and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Diabetes.

In The Last Decade

Louise Vedtofte

19 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Louise Vedtofte Denmark	13	554	248	205	174	162	19	746
Mette Axelsen Sweden	13	265 0.5×	94 0.4×	145 0.7×	252 1.4×	80 0.5×	20	666
Trine Vang Skjøth Denmark	12	1.1k 2.0×	344 1.4×	384 1.9×	304 1.7×	614 3.8×	23	1.3k
Rola Hammoud Canada	11	196 0.4×	106 0.4×	91 0.4×	102 0.6×	72 0.4×	24	491
E. Dall’Aglio Italy	12	324 0.6×	73 0.3×	153 0.7×	171 1.0×	40 0.2×	23	634
Bernard Job France	4	246 0.4×	159 0.6×	54 0.3×	126 0.7×	339 2.1×	7	619
Meera Shah United States	16	438 0.8×	542 2.2×	167 0.8×	376 2.2×	114 0.7×	38	1.0k
Arash Pakseresht Denmark	7	707 1.3×	233 0.9×	310 1.5×	257 1.5×	499 3.1×	12	975
Mads Frederik Rasmussen Denmark	7	838 1.5×	254 1.0×	378 1.8×	344 2.0×	480 3.0×	7	1.1k
Altynai Satylganova Denmark	9	471 0.9×	153 0.6×	199 1.0×	246 1.4×	342 2.1×	12	780
Louise Færch Denmark	7	720 1.3×	240 1.0×	279 1.4×	239 1.4×	414 2.6×	16	930

Countries citing papers authored by Louise Vedtofte

Since Specialization

Citations

This map shows the geographic impact of Louise Vedtofte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Vedtofte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Vedtofte more than expected).

Fields of papers citing papers by Louise Vedtofte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Vedtofte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Vedtofte. The network helps show where Louise Vedtofte may publish in the future.

Co-authorship network of co-authors of Louise Vedtofte

This figure shows the co-authorship network connecting the top 25 collaborators of Louise Vedtofte. A scholar is included among the top collaborators of Louise Vedtofte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise Vedtofte. Louise Vedtofte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Vedtofte, Louise, Camilla Andreasen, Anne L. Sørensen, et al.. (2023). Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial. Diabetes Obesity and Metabolism. 26(1). 201–214. 6 indexed citations

Vedtofte, Louise, Elisabeth R. Mathiesen, Jens Svare, et al.. (2021). 10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out. Diabetes. 70(Supplement_1). 1 indexed citations

Vedtofte, Louise, Jonatan I. Bagger, Camilla Andreasen, et al.. (2020). One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine. 9(10). 3213–3213. 19 indexed citations

Tomasik, Jakub, Nitin Rustogi, Julie Rask Larsen, et al.. (2020). Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. Schizophrenia Bulletin Open. 1(1). 3 indexed citations

Veedfald, Simon, Louise Vedtofte, Kirsa Skov‐Jeppesen, et al.. (2019). Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. The Journal of Clinical Endocrinology & Metabolism. 105(3). e502–e510. 15 indexed citations

Larsen, Julie Rask, Camilla Kara Svensson, Louise Vedtofte, et al.. (2018). High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums. 24(4). 441–452. 23 indexed citations

Hausner, Hélène, Andreas Brønden, David P. Sonne, et al.. (2018). Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity. Diabetes Obesity and Metabolism. 20(11). 2557–2564. 42 indexed citations

Svensson, Camilla Kara, Julie Rask Larsen, Louise Vedtofte, et al.. (2018). One‐year follow‐up on liraglutide treatment for prediabetes and overweight/obesity in clozapine‐ or olanzapine‐treated patients. Acta Psychiatrica Scandinavica. 139(1). 26–36. 48 indexed citations

Vedtofte, Louise, Filip K. Knop, & Tina Vilsbøll. (2017). Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Opinion on Drug Safety. 16(3). 387–396. 15 indexed citations

10.

Vedtofte, Louise, Camilla Andreasen, Jonatan I. Bagger, et al.. (2017). Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia. 60(7). 1344–1353. 12 indexed citations

11.

Larsen, Julie Rask, Louise Vedtofte, Hans Søe Riis Jespersen, et al.. (2017). Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry. 74(7). 719–719. 153 indexed citations

12.

Andreasen, Camilla, Louise Vedtofte, Charlotte Strandberg, et al.. (2016). Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. Diabetes Care. 40(1). 109–116. 56 indexed citations

13.

Vedtofte, Louise, Filip K. Knop, & Tina Vilsbøll. (2015). Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. Expert Review of Clinical Pharmacology. 8(3). 273–282. 1 indexed citations

14.

Larsen, Julie Rask, Louise Vedtofte, Jens J. Holst, et al.. (2014). Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open. 4(3). e004227–e004227. 18 indexed citations

15.

Vedtofte, Louise, Elisabeth R. Mathiesen, Jens Svare, et al.. (2013). The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open. 3(10). e003834–e003834. 9 indexed citations

16.

Knop, Filip K., et al.. (2013). Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. Regulatory Peptides. 186. 104–107. 21 indexed citations

17.

Christensen, Mikkel, Louise Vedtofte, Jens J. Holst, Tina Vilsbøll, & Filip K. Knop. (2011). Glucose-Dependent Insulinotropic Polypeptide. Diabetes. 60(12). 3103–3109. 285 indexed citations

18.

Vedtofte, Louise, Thora Bödvarsdóttir, C. F. Gotfredsen, et al.. (2009). Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regulatory Peptides. 160(1-3). 106–114. 13 indexed citations

19.

Vedtofte, Louise, Thora Bödvarsdóttir, Allan E. Karlsen, & R. Scott Heller. (2006). Developmental Biology of the Psammomys obesus Pancreas: Cloning and Expression of the Neurogenin-3 Gene. Journal of Histochemistry & Cytochemistry. 55(1). 97–104. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact